# A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

> **NCT03112603** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 330 (actual)

## Conditions studied

- Graft-versus-host Disease (GVHD)

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Extracorporeal photopheresis (ECP)
- **DRUG:** Low-dose methotrexate (MTX)
- **DRUG:** Mycophenolate mofetil (MMF)
- **DRUG:** mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
- **DRUG:** Infliximab
- **DRUG:** Rituximab
- **DRUG:** Pentostatin
- **DRUG:** Imatinib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03112603
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-29
- **Primary completion:** 2020-05-08
- **Final completion:** 2022-12-15
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03112603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03112603, "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03112603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*